CN109475633A - 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1 - Google Patents

在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1 Download PDF

Info

Publication number
CN109475633A
CN109475633A CN201780047962.4A CN201780047962A CN109475633A CN 109475633 A CN109475633 A CN 109475633A CN 201780047962 A CN201780047962 A CN 201780047962A CN 109475633 A CN109475633 A CN 109475633A
Authority
CN
China
Prior art keywords
antibody
months
dosage
subject
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780047962.4A
Other languages
English (en)
Chinese (zh)
Inventor
B.法萨奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109475633(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN109475633A publication Critical patent/CN109475633A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780047962.4A 2016-06-02 2017-06-01 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1 Pending CN109475633A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344880P 2016-06-02 2016-06-02
US62/344880 2016-06-02
PCT/US2017/035492 WO2017210453A1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Publications (1)

Publication Number Publication Date
CN109475633A true CN109475633A (zh) 2019-03-15

Family

ID=59067911

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780047962.4A Pending CN109475633A (zh) 2016-06-02 2017-06-01 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1

Country Status (17)

Country Link
US (3) US11083790B2 (https=)
EP (2) EP4248990A3 (https=)
JP (3) JP7175198B2 (https=)
KR (2) KR20230038318A (https=)
CN (1) CN109475633A (https=)
DK (1) DK3463457T3 (https=)
ES (1) ES2954139T3 (https=)
FI (1) FI3463457T3 (https=)
HR (1) HRP20230864T1 (https=)
HU (1) HUE062398T2 (https=)
LT (1) LT3463457T (https=)
PL (1) PL3463457T3 (https=)
PT (1) PT3463457T (https=)
RS (1) RS64388B1 (https=)
SI (1) SI3463457T1 (https=)
SM (1) SMT202300290T1 (https=)
WO (1) WO2017210453A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113677402A (zh) * 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
US11299543B2 (en) 2016-06-02 2022-04-12 Bristol-Myers Squibb Company Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
LT3463457T (lt) 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
EP3752193A4 (en) * 2018-02-13 2022-02-23 Merck Sharp & Dohme Corp. METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
CN104470949A (zh) * 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20060032289A1 (en) 2004-08-11 2006-02-16 Pinnaduwage Lal A Non-optical explosive sensor based on two-track piezoresistive microcantilever
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
LT3463457T (lt) 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470949A (zh) * 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CN104379169A (zh) * 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANAS YOUNES ET AL.: "Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin‘s lymphoma: a phase 1, open-label, dose-escalation study", 《LANCET ONCOL》 *
BATTY ET AL: "Doxorubicin，bleomycin，vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma：a 10-year follow-up study", 《LEUKEMIA&LYMPHOMA》 *
JOSEPH MALY & LAPO ALINARI: "Pembrolizumab in classical Hodgkin’s lymphoma", 《EUR J HAEMATOL》 *
MOSKOWITZ ET AL: "PD-1 Blockade with the Monoclonal Antibody Pembrolizumab（MK-3475）in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure：Preliminary Results from a Phase 1b Study（KEYNOTE-013）", 《BLOOD》 *
STEPHEN M ANSELL ET AL.: "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin‘s lymphoma", 《N ENGL J MED》 *
SUNSHINE ET AL.: "PD-1/PD-L1 inhibitors", 《CURR OPIN PHARMACOL》 *
YOUNES ET AL: "Nivolumab（nivo）in classical Hodgkin lymphoma（cHL）after autologous stem cell transplant（ASCT）and brentuximab vedotin（BV）-A phase 2 study", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113677402A (zh) * 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法

Also Published As

Publication number Publication date
EP4248990A3 (en) 2024-01-03
US20190290757A1 (en) 2019-09-26
SMT202300290T1 (it) 2023-11-13
EP4248990A2 (en) 2023-09-27
EP3463457A1 (en) 2019-04-10
LT3463457T (lt) 2023-09-11
HRP20230864T1 (hr) 2023-11-10
JP7175198B2 (ja) 2022-11-18
ES2954139T3 (es) 2023-11-20
US20220025049A1 (en) 2022-01-27
RS64388B1 (sr) 2023-08-31
DK3463457T3 (da) 2023-10-02
JP2025020119A (ja) 2025-02-12
JP2023025012A (ja) 2023-02-21
SI3463457T1 (sl) 2023-09-29
KR20230038318A (ko) 2023-03-17
WO2017210453A1 (en) 2017-12-07
FI3463457T3 (fi) 2023-09-12
PT3463457T (pt) 2023-09-07
KR20190015377A (ko) 2019-02-13
JP7568698B2 (ja) 2024-10-16
PL3463457T3 (pl) 2023-08-21
US20250134996A1 (en) 2025-05-01
US11083790B2 (en) 2021-08-10
EP3463457B1 (en) 2023-06-28
JP2019517504A (ja) 2019-06-24
HUE062398T2 (hu) 2023-10-28

Similar Documents

Publication Publication Date Title
US20250154257A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
US11866509B2 (en) Humanized antibodies against CEACAM1
CN109475633A (zh) 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
CN109476752A (zh) 抗-pd-1抗体与抗-cd30抗体的组合在淋巴瘤治疗中的用途
CN109476754A (zh) 抗-pd-1抗体在治疗结肠直肠癌患者中的用途
CN109475634A (zh) 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
CN109476753A (zh) 用于治疗肿瘤的方法的抗-pd-1抗体
KR20180128496A (ko) 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
US20230133118A1 (en) Compositions and methods for treating cancer
WO2018101448A1 (en) Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
NZ722296B2 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination